How ‘New Science’ Is Changing Healthcare
Listen now
If there’s one good thing that’s come from the pandemic, it’s this: Scientists and drug manufacturers came together in record time and with a shared purpose to create a safe and effective Covid-19 vaccine. In doing so, they set a precedent for medical advancements. So, where do we go from here? In this episode, we’ll talk about how biopharma companies can learn from last year’s disruption and harness what Accenture calls ‘New Science’ to rapidly discover and deliver revolutionary treatments and preparing for in the midst of regulatory and economic shifts. We’ll speak with Chris Gibson, C.E.O. and Co-Founder at Recursion; Stuart Henderson, Global Industry Lead — Life Sciences at Accenture; and David Coman, C.E.O at Science 37.
More Episodes
To thrive in the future, companies must rethink their growth strategies. A select group of companies, that Accenture calls Forerunners, recognize that emerging lifestyle shifts among consumers and investors will impact business in the future. But Forerunners are not just reacting to change. They...
Published 12/01/21
What is the cloud? Sure, it’s a place where photos and files can be stored for quick, easy and affordable access, but do companies understand what’s really possible in the cloud? In this episode, we learn that it can even help a brewery that has been in operation for more than 170 years pour the...
Published 11/10/21
Published 11/10/21